PTX3 and rheumatoid arthritis: In a larger monocentric cohort from China of untreated RA patients (n = 559) [1], anti-PTX3 prevalence was higher than in our sample (27% vs. 8.4%), while the proportion of anti-PTX3-positive patients was similar, independent of ACPA status (27.17% in ACPA+ vs. 25.56% in ACPA−).